AtriCure AFib treatment device wins FDA approval - MassDevice

AtriCure's EPi-Sense system, FDA-approved for long-standing persistent Afib, showed superior efficacy in the Converge trial. Hybrid AF therapy, a minimally invasive procedure, demonstrated significant improvements in Afib burden and freedom from arrhythmias, offering durable efficacy and enhancing electrophysiology lab efficiency.